Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30054343 | 1.00 | MTNR1A (0.61) | MTNR1AMTNR1BACHEHSD17B2CA1 | |
| SCHEMBL1134087 | 0.94 | MTNR1A (0.60) | MTNR1AMTNR1BACHEHSD17B2HSD17B1 | |
| SCHEMBL9005151 | 0.90 | MTNR1A (0.61) | MTNR1AMTNR1BACHEHSD17B2CA1 | |
| SCHEMBL22166438 | 0.89 | MTNR1A (0.60) | MTNR1AMTNR1BACHEHSD17B2HSD17B1 | |
| SCHEMBL12047760 | 0.87 | MTNR1A (0.58) | MTNR1AMTNR1BHSD17B2HSD17B1ALOX15 | |
| SCHEMBL3668117 | 0.87 | MTNR1A (0.58) | MTNR1AMTNR1BHSD17B2ALDH1A1CYP3A4 | |
| SCHEMBL17602315 | 0.87 | MTNR1A (0.62) | MTNR1AMTNR1BHSD17B2HSD17B1 | |
| SCHEMBL30595089 | 0.87 | MTNR1A (0.58) | MTNR1AMTNR1BHSD17B2ALDH1A1CYP3A4 | |
| SCHEMBL12048752 | 0.87 | MTNR1A (0.55) | MTNR1AMTNR1BACHEHSD17B2HSD17B1 | |
| SCHEMBL29636366 | 0.86 | ACHE (0.52) | MTNR1AMTNR1BACHEHSD17B2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111315829-B | Small molecule organic dye | 巴塞尔大学 | 2022-11-04 | — | — | CN | disclosed |
| US-11214687-B2 | Small-molecule organic dyes | UNIVERSITÄT BASEL (CH) | 2022-01-04 | — | — | US | disclosed |
| US-20200255667-A1 | SMALL-MOLECULE ORGANIC DYES | UNIVERSITÄT BASEL (CH) | 2020-08-13 | — | — | US | disclosed |
| EP-3676334-A1 | SMALL-MOLECULE ORGANIC DYES | Universität Basel (CH) | 2020-07-08 | — | — | EP | disclosed |
| CN-111315829-A | Small molecule organic dye | 巴塞尔大学 | 2020-06-19 | — | — | CN | disclosed |
| WO-2019057451-A1 | SMALL-MOLECULE ORGANIC DYES | UNIVERSITÄT BASEL (CH) | 2019-03-28 | — | — | WO | disclosed |
| US-20170213652-A1 | NOVEL SYNTHONS FOR DEVELOPING ORGANIC SEMICONDUCTORS | UNIVERSITÉ DE TOURS (FR) | 2017-07-27 | — | — | US | disclosed |
| US-20170213652-A1 | NOVEL SYNTHONS FOR DEVELOPING ORGANIC SEMICONDUCTORS | UNIVERSITÉ DE TOURS (FR) | 2017-07-27 | — | — | US | disclosed |
| WO-2016016221-A1 | NOVEL SYNTHONS FOR DEVELOPING ORGANIC SEMICONDUCTORS | UNIVERSITE DE TOURS FRANCOIS-RABELAIS (FR) | 2016-02-04 | — | — | WO | disclosed |
| EP-2285339-B1 | INITIATOR SYSTEM CONTAINING A DIARYLAKYLAMINE DERIVATIVE, HARDENABLE COMPOSITION AND USE THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2285339-B1 | INITIATOR SYSTEM CONTAINING A DIARYLAKYLAMINE DERIVATIVE, HARDENABLE COMPOSITION AND USE THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2012-12-19 | — | — | EP | disclosed |
| US-8314162-B2 | Initiator system containing a diarylalkylamine derivate, hardenable composition and use thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| EP-0891121-B1 | ORGANIC ELECTROLUMINESCENT ELEMENTS | TDK CORP (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20110077361-A1 | INITIATOR SYSTEM CONTAINING A DIARYLALKYLAMINE DERIVATE, HARDENABLE COMPOSITION AND USE THEREOF | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2011-03-31 | — | — | US | disclosed |
| EP-2285339-A1 | INITIATOR SYSTEM CONTAINING A DIARYLAKYLAMINE DERIVATIVE, HARDENABLE COMPOSITION AND USE THEREOF | 3M Innovative Properties Company (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009151957-A1 | INITIATOR SYSTEM CONTAINING A DIARYLAKYLAMINE DERIVATIVE, HARDENABLE COMPOSITION AND USE THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009151957-A1 | INITIATOR SYSTEM CONTAINING A DIARYLAKYLAMINE DERIVATIVE, HARDENABLE COMPOSITION AND USE THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-2133064-A1 | Initiator system containing a diarylalkylamine derivate, hardenable composition and use thereof | 3M Innovative Properties Company (US) | 2009-12-16 | — | — | EP | disclosed |
| EP-2133064-A1 | Initiator system containing a diarylalkylamine derivate, hardenable composition and use thereof | 3M Innovative Properties Company (US) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214687-B2 | Small-molecule organic dyes | SLC7A5, SLC30A5, ZKSCAN2 | MTNR1A 1186/4885MTNR1B 2147/4885ACHE 2219/4885 |
| US-20170213652-A1 | NOVEL SYNTHONS FOR DEVELOPING ORGANIC SEMICONDUCTORS | NES, NCL, CDK6 | MTNR1A 4501/4885MTNR1B 4552/4885ACHE 2682/4885 |
| US-20200255667-A1 | SMALL-MOLECULE ORGANIC DYES | SLC7A5, SLC30A5, ZKSCAN2 | MTNR1A 1186/4885MTNR1B 2147/4885ACHE 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.